Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Plus Sirolimus for Recurrent GBM
NCT00672243Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib and sirolimus in glioblastoma multiforme (GBM) and Gliosarcoma (GS), sponsored by Duke University. Primary endpoint: 6-month Progression-free Survival. Started Apr 2007; status: completed.
02
Drugs
erlotinibsirolimus
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00672243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672243.